Project Partners

A consortium of partners has been established to implement each of the Ebola vaccine projects.

EBOVAC1 Consortium Partners

London School of Hygiene & Tropical Medicine (UK) (coordinator)  
Janssen Vaccines & Prevention, B.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
INSERM (France) INSERM logo
University of Oxford (UK) Oxford logo
College of Medicine and Allied Health Science, University of Sierra Leone (Sierra Leone)

EBOVAC2 Consortium Partners

INSERM (France) (coordinator) INSERM logo
Janssen Vaccines & Prevention, B.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
Centre Muraz (Burkina Faso) Centre Muraz logo
Inserm Transfert (France) Impression
London School of Hygiene & Tropical Medicine (UK)  
University of Oxford (UK) Oxford logo

EBOVAC3 Consortium Partners

London School of Hygiene & Tropical Medicine (UK) (coordinator)
Janssen Vaccines & Prevention, B.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
INSERM (France)  INSERM logo
University of Antwerp (Belgium)  
College of Medicine and Allied Health Science, University of Sierra Leone (Sierra Leone)
University of Kinshasa, Democratic Republic of Congo
Coalition for Epidemic Preparedness Innovations

EBODAC Consortium Partners

London School of Hygiene & Tropical Medicine (UK)
Janssen Pharmaceutical, N.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Belgium) Janssen logo
Grameen Foundation (USA)  
World Vision of Ireland (Ireland)  World Vision logo

EBOMAN Consortium Partners

Vibalogics (Germany) (coordinator) Vibalogics logo
Janssen Vaccines & Prevention, B.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) (Netherlands) Janssen logo
Bavarian Nordic A/S (Denmark) Bavarian logo
These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
IMI EFPIA EU
Copyright © 2024 Ebovac | Terms and Conditions | WordPress development by Toast.